Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Andersen

Showing results (491-500 of 520) with videos related to

Pageof 52
Sort By:
Journal of Medicinal Chemistry|June 11, 2015
Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain InhibitorWylie S Palmer, Guillaume Poncet-Montange, Gang Liu, et al.
Epigenetics & Chromatin|September 24, 2015
Development of novel cellular histone-binding and chromatin-displacement assays for bromodomain drug discoveryYanai Zhan, Maria Kost-Alimova, Xi Shi, et al.
Molecular Cancer Therapeutics|January 27, 2025
LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant CancersLauren Catherine M Martires, Leanne G Ahronian, Charlotte B Pratt, et al.
Cancer Research|July 4, 2015
The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor StudiesBhavatarini Vangamudi, Thomas A Paul, Parantu K Shah, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|October 16, 2025
Tumor suppressor collateral damage screens reveal mRNA homeostasis protein HBS1L as a novel vulnerability in ch9p21 driven FOCAD deleted cancerHongxiang Zhang, Matthew R Tonini, Lauren Catherine M Martires, et al.
Ecology and Evolution|July 11, 2017
Bioclimatic transect networks: Powerful observatories of ecological changeStefan Caddy-Retalic, Alan N Andersen, Michael J Aspinwall, et al.
Cancer Research|June 10, 2026
TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Anti-Tumor Immunity and Immunotherapy EfficacyAlvin Ziying Lu, Brian B Haines, Wenhai Zhang, et al.
Molecular Cancer Therapeutics|October 13, 2022
Ubiquitinated PCNA Drives USP1 Synthetic Lethality in CancerAntoine Simoneau, Justin L Engel, Madhavi Bandi, et al.
Nature Communications|February 9, 2024
Amyloid-β aggregates activate peripheral monocytes in mild cognitive impairmentKristian Juul-Madsen, Peter Parbo, Rola Ismail, et al.
Nature Biomedical Engineering|April 25, 2019
Publisher Correction: Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugsMatthew R Golder, Jenny Liu, Jannik N Andersen, et al.
Pageof 52

Showing results (491-500 of 520) with videos related to

Sort By:
Pageof 52
Journal of Medicinal Chemistry|June 11, 2015
Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain InhibitorWylie S Palmer, Guillaume Poncet-Montange, Gang Liu, et al.
Epigenetics & Chromatin|September 24, 2015
Development of novel cellular histone-binding and chromatin-displacement assays for bromodomain drug discoveryYanai Zhan, Maria Kost-Alimova, Xi Shi, et al.
Molecular Cancer Therapeutics|January 27, 2025
LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant CancersLauren Catherine M Martires, Leanne G Ahronian, Charlotte B Pratt, et al.
Cancer Research|July 4, 2015
The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor StudiesBhavatarini Vangamudi, Thomas A Paul, Parantu K Shah, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|October 16, 2025
Tumor suppressor collateral damage screens reveal mRNA homeostasis protein HBS1L as a novel vulnerability in ch9p21 driven FOCAD deleted cancerHongxiang Zhang, Matthew R Tonini, Lauren Catherine M Martires, et al.
Ecology and Evolution|July 11, 2017
Bioclimatic transect networks: Powerful observatories of ecological changeStefan Caddy-Retalic, Alan N Andersen, Michael J Aspinwall, et al.
Cancer Research|June 10, 2026
TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Anti-Tumor Immunity and Immunotherapy EfficacyAlvin Ziying Lu, Brian B Haines, Wenhai Zhang, et al.
Molecular Cancer Therapeutics|October 13, 2022
Ubiquitinated PCNA Drives USP1 Synthetic Lethality in CancerAntoine Simoneau, Justin L Engel, Madhavi Bandi, et al.
Nature Communications|February 9, 2024
Amyloid-β aggregates activate peripheral monocytes in mild cognitive impairmentKristian Juul-Madsen, Peter Parbo, Rola Ismail, et al.
Nature Biomedical Engineering|April 25, 2019
Publisher Correction: Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugsMatthew R Golder, Jenny Liu, Jannik N Andersen, et al.
Pageof 52